RxDoctor Payments Data

Marc Miller, MD

Clinical Cardiac Electrophysiology · New York, NYNPI 1326133737

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.6% of it on its own, with 9 other manufacturers making up the rest.

$31,838in general payments, 2019–2025

Across 207 payments — averaging $153.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Medtronic$5K
  • Biotronik Inc.$4K
  • Abbott$2K
  • Cardiva Medical, Inc.$389
  • Cordis US CORP.$138
  • plus $268 from 4 others
$158,052in research payments, 2019–2025

Across 71 payments — averaging $2226.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$158K

What the payments were for

  • Consulting fees$4,46314%
  • Speaking & faculty fees$17,40055%
  • Travel & lodging$5,27617%
  • Food & beverage$4,69915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,838 in reported general payments places this provider in the 60th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$648,156
Medicare patients
2,657
Services billed
7,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$26,360
Metoprolol Succinate21$284
Amiodarone Hcl15$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$26,36033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →